Fight Aging!

Genes produce proteins at a pace determined by epigenetic control over nuclear DNA structure. That epigenetic control changes with age for reasons that are incompletely understood. A promising possibility is that repeated activation of DNA repair processes depletes specific factors needed for maintenance of DNA structure, but that needs further confirmation. The pace of protein production changes in a characteristic way with age for countless different proteins. Of that large number, some are known to cause harm, and are associated with aspects of degenerative aging. These are potential targets for gene therapies; I listed a large number of them some years ago, and that set has only grown since then.

Gene therapy technology has existed for decades, but is not yet very broadly used. A narrow subset of such therapies are becoming increasingly used in the medical tourism industry as potential treatments for aging. Why aren't we swimming in dozens of commercially available gene therapy implementations to dial up expression of gene X or dial down expression of gene Y to improve late life health? The short answer is that gene therapy has a delivery problem. It is somewhere between very hard and impossible to deliver gene therapies safely and effectively to most tissues in the body, given the tools presently available. The therapeutic applications being explored most aggressively these days largely fall into a small set of categories, where local delivery of a relatively small amount of a well-explored gene therapy vector (such as plasmids or AAV) does the job. For example, to turn a small number of fat cells into factories to produce a beneficial signaling protein that will circulate throughout the body - such as klotho, follistatin, and so forth. Or where a delivery mode can hit desired tissues with high specificity, such as intranasal delivery of AAV to reach parts of the brain.

Gene therapies that can reliably and selectively produce expression in a small inner organ require direct injection, which developers largely reject as an option outside the context of severe disease. Intravenous injection of gene therapy vectors that produce sufficient expression in a target inner organ without overloading the liver or bearing an unacceptably high risk of an immune reaction is an unsolved problem for near all target organs. Further, systemic injection of high dose gene therapy vectors has caused deaths in recent years, and is thus not in favor for anything but the most severe disease conditions. Being able to change gene expression in cells throughout the body with a single intravenous treatment (again without overloading the liver or provoking the immune system) also remains a pipe dream; while a few programs offer hope for progress on this front, no established gene therapy vectors are capable of doing this.

Partial epigenetic reprogramming is thought to offer the potential to bypass targeting of individual genes by rejuvenating the control over DNA structure and gene expression. But this approach still suffers from all of the delivery issues of gene therapy, alongside the likely need for different dosage and duration in different tissues. At the end of the day, yes, the technological capability exists to change the behavior of aging cells for the better. It is trivial to do so in a cell in a dish. The delivery challenges are what prevents the research and development communities from bringing this capability into patients in the near term. For now the field is focused on only a few genes, approaches, and tissues that are a good fit for the limited delivery capabilities that exist.

Gene therapy for aging and longevity

Over 2000 genes have been linked to increased longevity in a variety of models, but the translation of these findings into clinical applications remains challenging. Gene therapy is a potential strategy for extending healthspan by targeting genes associated with longevity or age-related diseases. This approach involves transferring genetic material directly into target tissue using viral or nonviral vectors, thereby enabling the augmentation, suppression, or precise editing of genes. This review examines multiple gene therapy strategies and their respective technical challenges, with a particular focus on identifying the most promising genetic targets for future interventions.

Many different gene delivery vectors have been engineered in recent decades. They can broadly be divided into physical, chemical, and virus-based methods. All gene delivery vehicles must overcome the same set of issues: efficient delivery to target locations, evasion of host immune responses, sufficient packaging size, controlled expression levels, reversibility and stability, redosability, and cost-effectiveness. In other words, each vector represents a multidimensional optimization problem in which certain existing properties determine whether a vector is more suitable for some applications over others. In the context of longevity therapies, additional requirements include a broad distribution profile, very-long-acting and stable expression, and high safety standards, as such interventions must remain effective over extended periods and are also intended for use in individuals without overt disease.

The main obstacle longevity gene therapies need to overcome is the ability to deliver the genes of interest to many or all tissues in the body. Most of the genes known to extend longevity are expressed intracellularly and across numerous tissues in the body. In this review, we identified multiple gene candidates from animal and human studies as potential targets for longevity gene therapies. Based on its advantages in gene delivery, AAV-mediated gene therapy is currently the most suitable platform for longevity gene therapy, but technical challenges remain, such as whole-body delivery and biomechanical limitations.

To accelerate the longevity gene therapy field, several key technical advancements are desirable. These include new AAV serotypes or vehicles for broader delivery across the body; better systems for controlled expression in individual organs, compact, reversible, or controllable expression systems; improved immunosuppressors to prevent anti-vector or anti-transgene immunity; compact molecular tools for safe and controlled integration; and new (possibly automated) production and quality control pipelines to reduce manufacturing costs.